ClinicalTrials.gov
ClinicalTrials.gov Menu

Study on the Role of Gamma Delta T Cells in Sepsis Immunosuppression and Its Molecular Mechanism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02361970
Recruitment Status : Completed
First Posted : February 12, 2015
Last Update Posted : May 23, 2017
Sponsor:
Information provided by (Responsible Party):
Kang Yan, West China Hospital

Brief Summary:
The purpose of the study is to evaluate the status and function of gamma delta T cells in peripheral blood of sepsis patients.

Condition or disease
Sepsis

Detailed Description:
Sepsis therapy is a prominent problem of the modern critical care medicine,and improving the level of sepsis treatment by immune intervention measures is a hot research topic with close attention.Gamma delta T cells is considered as one new T lymphocyte subset in recent years,which playing an important role in resistance to infection,anti-tumor and immune regulating function in the body.First,we played attention to the status and function of gamma delta T cells in peripheral blood of sepsis patients including differentiation marker,subtype and production of related cytokine,and then the molecular mechanism of insufficient gamma delta T cells.At the same time the responsibility of gamma delta T cells of sepsis patients to certain bacteria and viral antigen and the regulation of gamma delta T cells on other natural immune cells including NK cells and mononuclear cells were studied to identify the status and role gamma delta T cells in sepsis immunosuppression by culture in vitro.Further we studied the effect of specific stimulants on proliferation and activation of gamma delta T cells in patients with sepsis and also anti-infection acquired by gamma delta T cells,expecting as an entry point to explore new treatment strategy to sepsis.

Study Type : Observational
Actual Enrollment : 84 participants
Observational Model: Case-Control
Time Perspective: Prospective
Actual Study Start Date : May 2014
Actual Primary Completion Date : May 2015
Actual Study Completion Date : May 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sepsis

Group/Cohort
severe sepsis and septic shock
patients were diagnosed severe sepsis or septic shock
patient control
Patients after elective surgeries presented with SIRS but without sepsis
volunteer
Health persons



Primary Outcome Measures :
  1. The percentage of activated gamma delta T cells [ Time Frame: within 24h after recruitment ]

Secondary Outcome Measures :
  1. The percentage of apoptotic gamma delta T cells [ Time Frame: within 24h after recruitment ]

Biospecimen Retention:   Samples Without DNA
Peripheral blood sample was collected to examine extra-cell expression of gamma delta T cells and their intracellular cytokines with or without immuno-stimulants using flow cytometry.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients admitted in ICUs of West China Hospital
Criteria

Inclusion Criteria:

  • clinical symptoms of severe sepsis and septic shock
  • age over 18 years

Exclusion Criteria:

  • preexisting autoimmune disease
  • patients received immuno-suppressive treatment in the previous 6 months
  • patients with chronic infection,e.g.tuberculosis,hepatitis or HIV infection,etc.
  • pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02361970


Locations
China, Sichuan
West China Hospital,Sichuan University
Chengdu, Sichuan, China, 610041
Sponsors and Collaborators
West China Hospital

Responsible Party: Kang Yan, Director of Intensive Care Unit, West China Hospital
ClinicalTrials.gov Identifier: NCT02361970     History of Changes
Other Study ID Numbers: Sepsis-kyan0127
First Posted: February 12, 2015    Key Record Dates
Last Update Posted: May 23, 2017
Last Verified: May 2017

Keywords provided by Kang Yan, West China Hospital:
sepsis
gamma delta T cells
immunosuppression

Additional relevant MeSH terms:
Sepsis
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes